Eleusis SPAC
ELE-Psilo - Potentially Favorable Differentiation
Formulation
Onset / PK Design Attribute
Potential Duration of
Treatment Administration
Potential Monitoring Cost
Compatibility with
Existing (US) Reimbursement
Anticipated Infrastructure
Requirements
Safety Considerations
Psilocin
IV
Designed to be Immediate with Low
Variability
Simulated ≤ 2 hours
$350¹
Targeting Compatibility with Existing
Reimbursement Frameworks
Designed for Existing Clinical
Infrastructure
Phase I results
anticipated in 2022
Psilocybin
Oral
Observed to be Delayed and Highly Variable
in Clinical Studies
~6 hours
$3,150²
May Require New Reimbursement
Framework
New Infrastructure Potentially Required for
Prolonged Safety Monitoring2
Variable onset/duration of drug effect,
inability to terminate drug effect
5-MeO-DMT
Intranasal
Observed to be Immediate and Highly
Variable³
Unknown; duration affected by
individualized dosing regimen³
Unknown
Unknown
Unknown
Multiple administrations per treatment³;
incidence of reactivations/flashbacks5
1) Eleusis simulations based on primary data from Brown et al. 2017, Madsen et al. 2019, Hasler et al. 1997, and Carhart-Harris et al. 2011; 2) ELE-Psilo care delivery estimates based on 3 hours of psychiatric-mental health nurse involvement ($50 per hour) and 2 hours of
psychiatric oversight ($100 per hour); Oral psilocybin based on estimated hourly cost of a certified therapist ($150) and assumes 2 therapists and 1 supervising psychiatrist, and the current clinical trial paradigm (1 hour preparation session, one 6-hour dosing session, and 1
hour integration session). Rucker, J. et. al (2019) Psilocybin administration to healthy participants: safety and feasibility in a placebo-controlled study. Poster presented at the 58th Annual Meeting of The American College of Neuropsychopharmacology, Orlando, FL, USA, 8-11
December 2019 (treatment program); Carhart-Harris et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa2032994 (Supplement) (assumptions about therapist treatment); Occupational Employment
and Wages, May 2018, 29-1171 Nurse Practitioners. US Bureau of Labor Statistics (Nurse Practitioner rates); How Much Does Therapy Cost? (And Why Is It So Expensive?), The Talkspace Voice (October 29, 2015); Occupational Employment and Wages, May 2018, 29-1066
Psychiatrists. US Bureau of Labor Statistics (Psychiatrist rates) 3) GH Research Corporate Presentation, June 2021; 4) Weil, A. T., & Davis, W. (1994). Bufo alvarius: A potent hallucinogen, of animal origin. Journal of Ethnopharmacology, 41(1-2), 1-8.5) Uthaug, M.V., Lancelotta, 18
R., Ortiz Bernal, A.M., Davis, A.K., & Ramaekers, J.G. (2020). A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting. Journal of Psychedelic Studies.View entire presentation